Taste matters when it comes to oral contrast agents, and may affect patient compliance, according to a new study. Patients preferred diluted oral contrast agent iohexol (GE Healthcare’s Omnipaque) to diluted diatrizoate sodium (Mallinckrodt’s Gastroview) when undergoing abdominopelvic CT scanning.
Taste matters when it comes to oral contrast agents, and may affect patient compliance, according to a new study published in the American Journal of Roentgenology. Patients preferred diluted oral contrast agent iohexol (GE Healthcare’s Omnipaque) to diluted diatrizoate sodium (Mallinckrodt’s Gastroview) when undergoing abdominopelvic CT scanning.
The researchers found 81% of patients in their 300-person study preferred iohexol. Neither agent had flavoring added.
“The better taste with iohexol should improve patient compliance with drinking the necessary amount of contrast medium and improve overall satisfaction with the radiology experience,” said Dr. Michelle McNamara, a diagnostic radiologist and assistant professor at the University of Alabama-Birmingham, and lead author of the study.
In the prospective double-blinded study, patients were randomized to receive either iohexol or diatrizoate sodium, and graded the taste of the agents using a five-point scale.
As a secondary objective of the study, CT images were graded for bowel opacification by two blinded abdominal radiologists. The researchers found no difference in bowel opacification between the two agents.
“Receiving an oral contrast agent is often the least pleasant part of the radiology experience for a patient,” McNamara said. “Patients often complain of an unpleasant taste, and many experience gastrointestinal side effects such as nausea and vomiting. This may result in decreased satisfaction with the procedure and poor compliance with oral contrast dosing.”
The results of this study are positive but many radiology departments now spike their oral contrast agent with a flavored drink to improve the taste anyway, according to Dr. Jay Heiken, a professor of radiology and an abdominal imaging expert at Washington University in St. Louis.
“Some radiology departments, including my own, no longer routinely administer an oral contrast agent for body CT, making the comparison a moot point in those departments,” he said.
However, very ill patients might benefit from iohexol’s more acceptable flavor as they often have difficulty drinking oral contrast because of its taste, he said.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.